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Introduction
Endometriosis, which affects up to 1 in 15 women of
reproductive age,1 is progressive in nature, and is
characterized by symptoms such as pelvic tenderness,
induration, dysmenorrhea, dyspareunia, and chronic
pelvic pain. Endometriosis can also be an important
factor contributing to infertility.
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Background: The purpose of this study was to evaluate the efficacy and safety of nafarelin, a gonadotropin-releasing
hormone (GnRH) analogue, versus danazol in the treatment of women with endometriosis in Taiwan.
Methods: Fifty-nine women with laparoscopically and pathologically confirmed endometriosis were randomized to
receive nafarelin or danazol for 180 days. Efficacy was assessed from mean changes in laparoscopy score (LS)
and total symptom severity score (TSSS). Adverse events (AEs) and laboratory parameters, including hematology,
hepatic function, blood pressure, and lipid levels, were monitored for safety evaluations.
Results: All demographic and baseline factors, except body weight, were comparable between the 2 treatment groups.
Both nafarelin and danazol satisfactorily resolved pelvic tenderness, induration, pelvic pain, dysmenorrhea and
dyspareunia. No significant differences were noted in efficacy endpoints between nafarelin and danazol regarding
LS and TSSS at 90 and 180 days of treatment. No significant difference was observed between the 2 groups regarding
the overall incidence of AEs, except for laboratory-related AEs. However, nafarelin tended to have less impact than
danazol on aspartate transaminase and alanine transaminase, and nafarelin was better tolerated than danazol
regarding changes in lipid profiles. Both treatments had little or no effect on hematologic parameters.
Conclusion: Nafarelin and danazol demonstrated similar clinical efficacy, but nafarelin was associated with fewer
laboratory changes and a stable lipid profile, relative to danazol. Moreover, intranasally administered nafarelin is
noninvasive, and may be a more comfortable and safer alternative to slow-release injectable GnRH agonists. Based
on this study, we suggest that nafarelin, like other GnRH analogues, may be a treatment of choice for Taiwanese
women with endometriosis. However, direct comparative studies of nafarelin with slow-release injectable GnRH agonists
are now required. [J Chin Med Assoc 2005;68(7):307–314]
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Combined surgery (most appropriately through
laparoscopy) and medical treatment is currently
considered the optimal treatment for advanced
endometriosis.2–4 Medical treatment can be classed
as steroidal or nonsteroidal: danazol, a 17-_-
ethinyltestosterone derivative, represents the primary
steroidal intervention and has androgenic and anabolic
effects; whereas gonadotropin-releasing hormone
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(GnRH) agonists, which include buserelin, goserelin,
histrelin, leuprolide and nafarelin, are nonsteroidal
compounds used in the treatment of endometriosis.5
Both steroidal and nonsteroidal therapies, through
hypoestrogenism and ovarian quiescence, have dem-
onstrated efficacy in the treatment of endometriosis.
Selection of a particular treatment for endometriosis
depends largely on safety, tolerability, patient compliance
and, of course, economic considerations.
The androgenic and anabolic effects of danazol are
well known; the compound can, therefore, overcome
adverse effects (AEs) secondary to hypoestrogenism
and ovarian quiescence, including hot flushes, loss of
bone mineral density (osteoporosis), and many other
menopause-related signs and symptoms.6 However,
danazol may cause androgenic AEs such as weight
gain, edema, acne, seborrhea, reduced breast size,
hirsutism and, importantly, changes in lipid profile.7–9
Increased levels of low-density lipoprotein (LDL)
cholesterol and decreased levels of high-density
lipoprotein (HDL) cholesterol, which have been
demonstrated in previous clinical trials in danazol-
treated patients, pose significant concerns regarding
the risks of danazol-induced cardiovascular disease.8,10
Intranasal nafarelin acetate is a GnRH agonist that
has proven to be similarly effective to danazol, but
with superior safety and tolerability.8,11 Nafarelin is
formulated as an intranasal spray, and is absorbed into
the systemic circulation with a time to peak plasma
concentration (Tmax) of 18.4 minutes, and peak plasma
concentration (Cmax) of 2.04 mg/L.
12,13 The
pharmacokinetic profile and high biologic potency of
nafarelin would appear to facilitate use of the compound
as an effective and noninvasive treatment in the long-
term management of endometriosis.1
This study of intranasal nafarelin 400 μg daily
versus oral danazol 600 mg daily aimed to provide
more information, particularly about probable
equivalence of efficacy and effects on lipid profiles, in
the treatment of endometriosis in Taiwanese women.
Methods
Study population
Before initiation of this randomized, parallel,
comparative study, approval was granted by the
independent ethics committee and institutional review
board at Taipei Veterans General Hospital, Taipei,
Taiwan, and by the Department of Health, Executive
Yuan, Republic of China.
Fifty-nine consecutive women with a histologically
proven diagnosis of endometriosis via laparoscopy
entered the study. Recruitment started in January
1998 and ended in October 2000. Subjects were aged
18–48 years, and were adequately protected from
pregnancy with a method other than hormonal
contraception. Laparoscopy to establish a diagnosis,
and the need for treatment, of endometriosis was
performed within the 3 months before study
participation. Laparoscopic excision of ovarian
endometrioma, and lysis of severe adhesions, was also
performed at this time, if necessary.
Patients who satisfied the inclusion criteria gave
written informed consent before starting the trial.
Exclusion criteria comprised pregnancy or breast-
feeding, menopausal or postmenopausal status, use of
estrogen, progesterone, or contraceptive steroids in
the previous 3 months, impaired hepatic or renal
function, cardiovascular disease, acquired immune
deficiency syndrome or other sexually transmitted
diseases.
Study protocol
All eligible patients entered the trial on the third to
tenth day of their menstrual cycles and were randomized
to 1 of 2 groups: intranasal nafarelin acetate (Synarel®;
Searle Pharma Ltd, Chicago, IL, USA) 200 μg twice
daily (2 200-μg sprays in alternating nostrils); or oral
danazol (DanocrineTM; Sanofi-Synthelabo Australia
Pty Ltd, North Ryde, NSW, Austalia) 600 mg daily
(1 200-mg tablet 3 times per day). The duration of
nafarelin or danazol treatment was 180 days.
At the baseline examination on day 1, HDL-,
LDL- and total-cholesterol levels, and triglycerides,
were measured. Lipid levels, total symptom severity
score (TSSS), and AEs were assessed on days 30, 90,
120, and at the end of treatment. Hematologic and
hepatic function tests were performed at baseline and
at the final study visit. Laparoscopy for efficacy
evaluations was performed before and at the completion
of treatment. Efficacy variables comprised the
endometriosis TSSS and laparoscopic score (LS). The
TSSS consists of 5 measures: pelvic tenderness and
induration assessed by investigators, and pelvic pain,
dysmenorrhea and dyspareunia evaluated by patients.
The LS and staging used in this study were standards
from the revised American Fertility Society classification
of endometriosis (1985).14
Statistical analysis
Demographic and baseline characteristics were
tabulated by descriptive statistics (Table 1), and results
are described as mean ± standard deviation (SD) and
medians for parametric analysis. Differences between
the 2 groups were assessed by Fisher’s exact test,
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Chi-squared test, Cochran-Mantel-Haenszel or
Wilcoxon rank-sum test. Efficacy variables and
laboratory parameters were analyzed using the
Wilcoxon rank-sum test for between-group
comparisons, and the Wilcoxon signed-rank test for
within-group comparisons. Significance was set at a p
value of less than 0.05 in all statistical tests.
Results
Demographic and baseline characteristics
All 59 patients were considered as the intent-to-treat
population, with a similar number of patients given
nafarelin (n = 29) or danazol (n = 30) (Table 1).
Nafarelin recipients had a significantly lower mean
body weight than danazol-treated patients (51.2 vs
54.7 kg, p = 0.037), but there were no significant
differences between the 2 groups in terms of age,
obstetric and medical history, and menstrual history
and pattern. Six of 29 nafarelin recipients (20.7%) and
5 of 30 danazol-treated patients (16.7%) complained
of infertility. In the nafarelin group, 55% of patients
underwent combined extensive surgery and medical
treatment, whereas 50% of patients in the danazol
group did so; mean LS, TSSS and laparoscopic staging
at baseline were comparable between the 2 groups.
Clinical efficacy
Forty-one of 59 patients (22 nafarelin and 19 danazol
recipients) who completed 90 days’ treatment, and
who underwent laparoscopic examinations before and
after treatment, qualified for the efficacy evaluation. In
both treatment groups, improvements in TSSS from
baseline to days 90 and 180 were statistically significant
in almost all of the 5 items used to evaluate symptoms.
In the nafarelin group, decreased levels of pelvic pain
were noted at days 90 and 180, but these decreases
were not statistically significant. After 180 days of
nafarelin therapy, pelvic tenderness was completely
resolved (62% of patients), or of only mild severity
(38%). Among danazol-treated patients, 58% had
complete resolution of pelvic tenderness, whereas
10.5% had moderate, and 32% mild, symptoms
remaining. Regarding net change in TSSS, no
significant between-group difference was noted after
90 days (–4.4 ± 2.7 [nafarelin] vs –4.1 ± 1.7 [danazol];
p = 0.901) or 180 days (–4.2 ± 2.4 vs –4.6 ± 1.7;
p = 0.502) (Table 2).
The LS before treatment was similar in nafarelin
versus danazol recipients (28.7 ± 25.9 vs 29.7 ± 29.5;
p = 1.000). Regarding net change in LS from baseline
to day 180, both treatments reduced LS (–4.2 ± 10.7
[nafarelin] vs –0.3 ± 14.6 [danazol]). This between-
group difference was not statistically significant
(p = 0.541); however, the decrease of 4.2 from baseline
in the nafarelin group was statistically significant
(p = 0.047), whereas that of 0.3 in the danazol group
was not (p = 0.453). Endometriosis and adhesion
components of LS revealed that the overall decrease in
Table 1. Demographic and baseline characteristics*
Nafarelin (n = 29) Danazol (n = 30) p†
Age, yr 34.8 ± 6.6 32.4 ± 7.2 0.242
Body weight, kg 51.2 ± 5.2 54.7 ± 6.5 0.037‡
Menarche, age (yr) 13.7 ± 1.2 13.6 ± 1.4 0.975
Cycle length, d 5.4 ± 1.8 6.0 ± 2.0 0.150
Para 0.8 ± 1.1 1.0 ± 1.2 0.456
Systolic BP, mmHg 108.1 ± 8.6 106.1 ± 8.2 0.462
Diastolic BP, mmHg 72.8 ± 8.8 72.2 ± 7.5 0.896
LDL-cholesterol, mg/dL 118.5 ± 33.2 111.0 ± 25.0 0.362
HDL-cholesterol, mg/dL 55.7 ± 9.7 51.2 ± 11.3 0.105
Total cholesterol, mg/dL 190.7 ± 33.5 178.4 ± 27.7 0.125
Triglycerides, mg/dL 96.4 ± 86.8 73.4 ± 33.7 0.376
Baseline LS 28.0 ± 28.5 23.1 ± 26.4 0.395
Baseline TSSS 6.3 ± 3.2 6.1 ± 2.7 0.975
Presence of ovarian endometrioma
16 (55.0) 15 (50.0) 0.863
with surgical excision, n (%)
Stage I, n (%) 5 (17.0) 8 (26.0) 0.323
*Data shown are mean ± standard deviation, except for the bottom 2 rows which are number (%) of patients; †between-group p values were calculated
by the Wilcoxon rank-sum test; ‡p < 0.05.
BP = blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; LS = laparoscopic score; TSSS = total symptom severity score.
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LS after nafarelin treatment was due primarily to
alleviation of endometriosis, not adhesion (data not
shown). Neither nafarelin nor danazol eradicated
endometriosis spots completely; therefore, none of
the 13 women with stage I endometriosis was cured
with nafarelin (n = 5) or danazol (n = 8). Danazol did
not significantly reduce LS, or endometriosis or
adhesion scores.
Lipid profile
Forty-four of 59 patients (21 nafarelin and 23 danazol
recipients) who received study medication for at least
90 days, and who had serum lipid data available both
before and after treatment, were included in the
evaluation of lipid-profile changes (Table 3). Nafarelin
versus danazol recipients had a significantly smaller
increase in mean LDL-cholesterol level from baseline
to days 90 and 180. However, the actual mean LDL-
cholesterol level after 180 days’ treatment was not
significantly different between the nafarelin and danazol
groups. Although danazol-treated patients tended to
have an elevated LDL-cholesterol level after 90 days’
treatment, there was no further significant increase in
this parameter with another 90 days of treatment.
Table 2. Comparison of clinical efficacy between nafarelin and danazol*
After 90 days’ treatment After 180 days’ treatment
Nafarelin (n = 22) Danazol (n = 19) p† Nafarelin (n = 22) Danazol (n = 19) p†
Net change in TSSS –4.4 ± 2.7 –4.1 ± 1.7 0.901 –4.2 ± 2.4 –4.6 ± 1.7 0.502
Pelvic tenderness –0.9 ± 1.0 –0.7 ± 0.9 0.948 –0.9 ± 1.0 –0.7 ± 0.8 0.820
Induration –0.5 ± 0.9 –0.4 ± 0.7 0.868 –0.5 ± 0.8 –0.7 ± 0.8 0.544
Pelvic pain –0.3 ± 0.7 –0.5 ± 0.8 0.815 –0.2 ± 0.6 –0.5 ± 0.7 0.172
Dysmenorrhea –2.0 ± 0.9 –2.1 ± 1.0 0.664 –2.0 ± 0.9 –2.4 ± 0.8 0.196
Dyspareunia –0.6 ± 1.2 –0.4 ± 0.6 0.921 –0.6 ± 1.0 –0.2 ± 0.6 0.346
Net change in LS ND ND ND –4.2 ± 10.7 –0.3 ± 14.6 0.541
*Data shown are mean ± standard deviation; †between-group p values were calculated by the Wilcoxon rank-sum test.
LS = laparoscopic score; ND = no data; TSSS = total symptom severity score.
Table 3. Within- and between-group comparisons of serum lipid levels in nafarelin and danazol recipients*
Baseline After 90 days After 180 days
90-day 180-day
net change net change
LDL-cholesterol, mg/dL
Nafarelin (n = 21) 117.6 ± 35.6 124.0 ± 35.4 134.0 ± 37.5† 6.6 ± 30.6 13.9 ± 21.9
Danazol (n = 23) 110.7 ± 27.0 144.0 ± 31.4‡ 146.1 ± 46.4§ 31.5 ± 33.5 34.3 ± 47.4
p 0.267 0.089 0.382 0.026|| 0.033
HDL-cholesterol, mg/dL
Nafarelin (n = 21) 55.4 ± 10.5 56.7 ± 12.9 58.3 ± 9.0 1.3 ± 7.1 2.4 ± 8.2
Danazol (n = 23) 52.1 ± 12.2 29.4 ± 5.4‡ 31.4 ± 6.1 –21.3 ± 9.9 –20.6 ± 10.4
p 0.159 0.000 0.000 0.000|| 0.000||
Total cholesterol, mg/dL
Nafarelin (n = 21) 190.1 ± 36.1 199.8 ± 39.4 198.4 ± 38.0 8.2 ± 34.3 14.2 ± 25.3
Danazol (n = 23) 179.4 ± 29.6 181.3 ± 28.9 186.7 ± 39.0 –0.1 ± 33.2 2.4 ± 32.9
p 0.136 0.134 0.317 0.459 0.360
Triglycerides, mg/dL
Nafarelin (n = 21) 102.0 ± 95.5 112.4 ± 152.4 75.4 ± 26.4 10.4 ± 150.5 –21.7 ± 94.0
Danazol (n = 23) 76.0 ± 36.6 67.3 ± 30.0 75.4 ± 41.6 –10.3 ± 27.0 –1.7 ± 32.4
p 0.555 0.188 0.822 0.156 0.915
*Data shown are mean ± standard deviation; within-group statistical significance (vs baseline) was calculated by the Wilcoxon signed-rank test
— †p = 0.015, ‡p < 0.001, §p = 0.002; ||between-group statistical significance was calculated by the Wilcoxon rank-sum test.
HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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Nafarelin recipients had a relatively stable mean
HDL-cholesterol level throughout the study, whereas
danazol-treated patients had a clear drop in this
parameter, from 52.1 mg/dL at baseline to 29.4 mg/
dL at day 90 (p < 0.001); however, there was no
further decrease in mean HDL-cholesterol level in the
danazol group from day 90 to 180. Overall, 90- and
180-day net changes in mean HDL-cholesterol level
revealed a small increase in nafarelin recipients and a
marked decrease in danazol-treated patients; differences
between the 2 treatment groups were highly statistically
significant (p < 0.001).
Total cholesterol levels for nafarelin and danazol
recipients appeared to remain relatively constant
throughout the study, whereas triglyceride levels
fluctuated in both treatment groups; however, none
of the within- or between-group comparisons was
statistically significant, thus implying that neither
treatment had a marked effect on triglyceride levels.
Hematology and liver function tests
Hematologic changes associated with both treatments
are shown in Table 4. White blood cell (WBC) count
remained relatively constant throughout the study in
the nafarelin group, but increased significantly in the
danazol group. The between-group comparison of
mean WBC count revealed that danazol caused a
significantly (p = 0.032) greater increase in this
parameter than nafarelin; however, this difference
was unlikely to be clinically significant because all
values for mean WBC count remained within the
normal range.
Mean values for red blood cell (RBC) count,
hemoglobin (Hb), hematocrit (Hct), and platelet
count, were all within normal limits. Values for RBC
count, Hb, Hct and platelet count remained relatively
stable in nafarelin recipients, whereas a trend towards
increased values for these parameters was noted from
baseline to day 180 in danazol-treated patients.
Between-group differences regarding net changes in
RBC count, Hb, Hct and platelet count were statistically
significant, but of little clinical relevance because all
values remained within acceptable limits.
Baseline and post-treatment serum levels of alkaline
phosphatase (ALP), alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) are documented
Table 4. Within- and between-group comparisons of changes in hematologic parameters in nafarelin and danazol recipients*
Nafarelin Danazol
p||
n Mean ± SD n Mean ± SD
WBC, cells/mm3
Baseline 28 5,190 ± 1,485 27 5,772 ± 1,309
Day 180 24 5,340 ± 1,521 23 6,360 ± 1,515†
Net change 0.4 ± 1,330 892 ± 1,468 0.032
RBC, ×106 cells/mm3
Baseline 28 4.3 ± 0.5 27 4.4 ± 0.3
Day 180 24 4.3 ± 0.4 23 5.0 ± 0.4‡
Net change 0.1 ± 0.3 0.6 ± 0.5 0.001
Hemoglobin, g/dL
Baseline 28 12.6 ± 1.1 27 12.2 ± 1.6
Day 180 24 13.1 ± 1.1§ 23 14.0 ± 1.5‡
Net change 0.4 ± 0.6 1.6 ± 1.3 0.000
Hematocrit, %
Baseline 28 38.0 ± 3.6 27 37.0 ± 4.5
Day 180 24 38.6 ± 3.2 23 41.8 ± 3.5‡
Net change 0.5 ± 2.6 4.5 ± 4.1 0.001
Platelet count, cells/mm3
Baseline 28 237,786 ± 60,423 27 284,815 ± 65,577
Day 180 24 222,917 ± 50,646 23 331,652 ± 69,582‡
Net change –5,174 ± 38,007 56,762 ± 57,850 0.001
*Data shown are mean ± standard deviation; within-group statistical significance (vs baseline) was calculated by the Wilcoxon signed-rank test
— †p = 0.009, ‡p < 0.001, §p = 0.003; ||between-group statistical significance was calculated by the Wilcoxon rank-sum test.
SD = standard deviation; RBC = red blood cell count; WBC = white blood cell count.
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in Table 5. Nafarelin significantly increased the mean
ALP level from baseline (+25.7%, p < 0.001), whereas
danazol had no significant effect on this parameter.
Conversely, both nafarelin and danazol significantly
increased mean ALT and AST levels from baseline.
The magnitude of the ALT increase was significantly
smaller in nafarelin than danazol recipients (p =
0.028), and that of the AST increase tended, not
significantly, to be smaller in nafarelin than danazol
recipients (p = 0.084). Mean baseline and post-
treatment values for liver function indices were within
normal ranges in the nafarelin group, and ALP and
AST values in the danazol group generally returned to
normal after treatment was stopped. However, after
treatment withdrawal, the mean ALT level in danazol-
treated patients remained above normal limits, a finding
consistent with the previously documented negative
impact of danazol on hepatic function.
Adverse events
A total of 592 AEs were reported: 262 in the nafarelin
group and 330 in the danazol group. No significant
between-group difference was noted in the overall
incidence of AEs. Twenty-four of 29 patients in the
nafarelin group (82.8%), and 29 of 30 patients in the
danazol group (96.7%), experienced at least 1 AE. In
the nafarelin group, the most frequent AEs were
vaginitis and vasodilation (each with an incidence of
24.1%), followed by weight gain, leukorrhea, menstrual
disorders, and chest pain (10.3%). In the danazol
group, the most common AE was weight gain
(40.0%), followed by acne, vaginal hemorrhage, and
generalized spasm (each with an incidence of 20.0%),
vaginitis (16.7%), pain and hypertonia (13.3%), and
leukorrhea, menstrual disorders, asthenia, constipation,
pharyngitis, abdominal pain, rash, voice alteration,
and vulvovaginal disorders (10%). Significantly more
patients in the nafarelin than danazol group had hot
flashes (24% vs 0%, p = 0.005), whereas significantly
fewer had weight gain (10% vs 40%, p = 0.015). Only
patients in the danazol group experienced generalized
spasm (20%).
Discussion
Steroidal therapy with danazol, because of its
satisfactory clinical efficacy, has traditionally been the
standard treatment for endometriosis. However, the
negative impact of danazol on lipid profiles, especially
the well-documented effects of increased LDL-
cholesterol and reduced HDL-cholesterol concen-
trations, has raised concerns about the potential
for increased cardiovascular risks to patients.
Conversely, GnRH agonists have made possible the
nonsteroidal treatment of endometriosis by medical
castration. These compounds are rapidly inactivated
by gastrointestinal enzymes after oral administration;
therefore, alternative routes of administration,
including intravenous, intramuscular, or subcutaneous
injection, are required to achieve the desired therapeutic
effect. The need for safer, noninvasive, and more
Table 5. Within- and between-group comparisons of hepatic function test results in nafarelin and danazol recipients*
Nafarelin Danazol
p
n Mean ± SD n Mean ± SD
ALP (U/L)
Baseline 25 55.7 ± 16.1 28 55.8 ± 14.3
Day 180 23 70.0 ± 19.6† 20 52.1 ± 21.0
Net change 15.0 ± 13.9 –3.1 ± 15.4 0.001||
AST (U/L)
Baseline 26 19.8 ± 8.4 28 16.7 ± 3.8
Day 180 23 25.2 ± 14.5‡ 20 29.5 ± 12.5†
Net change 6.4 ± 12.6 12.2 ± 13.0 0.084
ALT (U/L)
Baseline 26 15.3 ± 12.0 28 14.7 ± 9.5
Day 180 23 25.7 ± 20.5§ 20 46.7 ± 41.1†
Net change 11.6 ± 19.0 31.0 ± 38.8 0.028||
*Data shown are mean ± standard deviation; within-group statistical significance (vs baseline) was calculated by the Wilcoxon signed-rank test
— †p < 0.001, ‡p = 0.027, §p = 0.012; ||between-group statistical significance was calculated by the Wilcoxon rank-sum test.
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase.
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convenient methods for administering GnRH agonists
led to the development of intranasal nafarelin.
In the current study, no statistically significant
difference was noted between nafarelin and danazol
regarding efficacy endpoints. Both nafarelin and
danazol satisfactorily resolved pelvic tenderness,
induration, pelvic pain, dysmenorrhea, and dyspa-
reunia. Our data confirm the previous findings of
Henzl and Kwei,11 who reported that 47–57% of
patients had complete symptom relief, and 38–45%
had only mild symptoms, after treatment with nafarelin
400 μg per day. In our study, only nafarelin recipients
experienced a statistically significant change in LS
from baseline to day 180 (net score change –4.2;
percent score change –14.6%; p = 0.047); there was
no major change in LS in danazol-treated patients.
These findings disagree with those of Henzl and
Kwei,11 who reported a decrease of 43–48% in LS
after treatment with nafarelin 400 μg/day, and a
decrease of approximately 49% after treatment with
danazol 600 mg/day.
Regarding lipid-profile effects in our study, mean
LDL-cholesterol level increased from 110.7 mg/dL
at baseline to 146.1 mg/dL after danazol therapy; a
smaller increase in this parameter (+16.4 mg/dL) was
noted in nafarelin-treated patients. Danazol recipients
also had a significantly lower mean HDL-cholesterol
level than nafarelin-treated patients, in whom HDL-
cholesterol concentrations remained relatively constant
throughout the study. The negative lipid-profile effects
of danazol were similar to those found in previous
studies.1,15,16 However, the lipid-profile effects of
nafarelin identified in other studies,8,10 i.e. increased
HDL-cholesterol concentrations and relatively
constant LDL-cholesterol concentrations, were not
found in our study. Despite such discrepant results, it
seems clear that nafarelin has lipid-profile effects that
are superior to those of danazol; thus, it has been
suggested that nafarelin may have a clinical advantage
over danazol regarding the potential for lower
cardiovascular risk.
In our study, a lower incidence of AEs was observed
in the nafarelin than danazol group; this finding was
consistent with a previous study report.16 All AEs in
our trial were mild to moderate in intensity, except for
1 allergic reaction in the nafarelin group. Hot flashes
and reduced libido in nafarelin recipients were noted
less frequently than in a previous trial,11 in which up to
90% and 22% of patients experienced hot flashes and
reduced libido, respectively. Bone mineral density
may be reduced because of hypoestrogenism, but our
study did not evaluate changes in this parameter in
nafarelin and danazol recipients. Indeed, given our
relatively short study duration (180 days), an evaluation
of changes in bone mineral density may not have been
clinically relevant. In major multinational studies
comparing nafarelin with danazol, nafarelin appeared
to increase ALP level and WBC count, and danazol
seemed to increase ALT and AST levels, WBC count,
and Hct.1 We found similar results in this trial.
As Taiwan has a high prevalence of hepatitis, and
as danazol is largely metabolized by the liver, the
marked negative effects of danazol on hepatic function
should be carefully considered in patients with active
hepatitis. The need for further studies on the effects
of danazol in patients with hepatitis may now be an
important issue in Taiwan. Additional studies are also
needed to directly compare the efficacy and safety of
intranasal nafarelin with that of other GnRH agonists.
Such studies may confirm intranasally administered
nafarelin as a more comfortable, less invasive, and
safer alternative to slow-release, injectable GnRH
agonists, which are expensive, and which may be
inappropriate for long-term treatment because of the
potential for reduced bone mineral density.6,17
Meanwhile, the current study clearly demonstrated
that nafarelin and danazol were equally effective in
endometriosis, although nafarelin was better tolerated
regarding certain AEs, laboratory changes, and
maintenance of a relatively stable lipid profile.
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